| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 24, 2006
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2007 on Tuesday, Oct. 31, 2006 at approximately 8:30 a.m. (ET). The...
-
Oct 9, 2006
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today welcomed Joe Papa as its President and Chief Executive Officer. Mr. Papa succeeds Dave Gibbons who is now the Company's Executive Chairman of...
-
Oct 3, 2006
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) will conduct a brief conference call at 10:00 a.m. (ET) on October 10, 2006 introducing Joe Papa as President and Chief Executive Officer. There will be...
-
Oct 2, 2006
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has been granted tentative approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application...
-
Sep 25, 2006
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market over-the- counter (OTC)...
-
Sep 11, 2006
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors has elected Joseph C. Papa as its President and Chief Executive Officer effective October 9. Mr. Papa...
-
Sep 1, 2006
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Perrigo Israel Pharmaceuticals subsidiary has been granted tentative approval from the U. S. Food and Drug Administration...
-
Aug 11, 2006
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0425 per share, payable on September 19, 2006 to shareholders of...
-
Aug 9, 2006
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for the full year and fourth quarter ended July 1, 2006. Perrigo Company (in thousands, except per share amounts) Fourth...
-
Aug 7, 2006
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, InvaGen Pharmaceuticals, Inc., has received tentative approval from the U.S. Food and Drug Administration (FDA) on...